Vaxess offers the MIMIX™ transdermal patch, a needle‑free delivery system that uses dissolvable microarray tips to administer vaccines and biologic therapies through the skin without refrigeration. The platform supports a wide range of molecules—including peptides, proteins, mRNA, and small‑molecule drugs—and is aimed at pharmaceutical developers and health organizations requiring cold‑chain‑independent, self‑administered solutions.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients and healthcare systems often rely on injectable needles and refrigerated cold chains to administer vaccines and biologic therapies, creating barriers for self‑administration, increasing waste, and limiting access in low‑resource environments.
Solution
Vaxess offers the MIMIX™ transdermal patch and applicator, a needle‑free delivery platform that uses dissolvable microarray tips composed of engineered biomaterials to deposit precise therapeutic doses through the skin. The patch eliminates the need for refrigeration, enabling stable storage and transport in settings without reliable cold‑chain infrastructure. By leveraging micro‑fabrication and controlled‑release chemistry, the system supports a broad portfolio of molecules—including peptides, mRNA vaccines, and GLP‑1 analogues—while maintaining bioavailability comparable to traditional injections. The self‑administered design reduces reliance on trained personnel and lowers administration costs, facilitating broader distribution of next‑generation treatments.
Target Audience
Primary customers are pharmaceutical and biotech companies developing injectable biologics or vaccines, as well as global‑health organizations and clinics operating in low‑resource or remote settings that require cold‑chain‑independent, self‑administered delivery solutions.
Features
- Dissolvable microarray tip array fabricated from high‑purity polymeric biomaterials for rapid, dose‑accurate skin penetration
- Integrated applicator mechanism that ensures consistent insertion depth and uniform payload release without user‑level variability
- Refrigeration‑free formulation stability achieved through lyophilized drug loading within the microarray matrix
- Compatibility with diverse therapeutic classes (peptides, proteins, nucleic acids, small molecules) via modular payload loading processes
- Scalable roll‑to‑roll manufacturing workflow that supports high‑volume production while maintaining tight tolerances on tip geometry
- Built‑in tamper‑evident packaging and ISO‑compliant sterility assurance for safe home or field use
- Real‑time adherence monitoring via optional NFC tag that logs patch activation and can integrate with digital health platforms